Rabbit Anti-Human AGK (a.a. 15-300) Polyclonal antibody

We develop an approach for calculating the inclusive multigluon production within the JIMWLK high energy evolution. We give a formal expression of multigluon cross section in terms of a generating functional for arbitrary number of gluons n. In the dipole limit the expression simplifies dramatically. We recover the previously known results for single and double gluon inclusive cross section and generalize those for arbitrary multigluon amplitude in terms of Feynman diagramms of Pomeron-like objects coupled to external rapidity dependent field s(eta). We confirm the conclusion that the AGK cutting rules in general are violated in multigluon production. However we present an argument to the effect that for doubly inclusive cross section the AGK diagramms give the leading contribution at high energy, while genuine violation only occurs for triple and higher inclusive gluon production. We discuss some general properties of our expressions and suggest a line of argument to simplify the approach further.

Acylglycerol kinase (AGK) had been shown to contribute to cancer progression and unfavorable clinical outcomes of patients. Our study aimed to investigate the expression pattern and clinical significance of AGK in patients with early-stage cervical squamous cell cancer (CSCC). The protein and messenger RNA (mRNA) expression of AGK was analyzed in six cervical cancer cell lines and four paired earlystage CSCC specimens and normal cervical tissues (NCT), using Western blotting and real-time PCR (RT-PCR). And we investigated the AGK protein expression in paraffin-embedded specimens from 140 patients with early-stage CSCC and 30 cases of NCT by immunohistochemistry (IHC). Statistical analyses were performed to evaluate the clinicopathological significance of AGK expression. The expressions of AGK protein and mRNA were significantly upregulated in cervical cancer cell lines and cancer tissues. IHC analyses revealed that AGK was highly expressed in 93 (66.4%) of 140 early-stage CSCC specimens, but in none of the NCT. Moreover, AGK expression in early-stage CSCC was significantly correlated with tumor stage (P<0.001), tumor size (P<0.001), and tumor type (P<0.001). Early-stage CSCC patients with high AGK expression level had shorter progress-free survival (PFS) and overall survival (OS) time compared with patients with low AGK expression levels. Univariate and multivariate analyses identified AGK expression level as an independent prognostic factor for survival of early-stage CSCC patients. We showed that AGK was over-expressed in cervical cancer cell lines and clinical tissues, and over-expression of AGK was associated with poor survival outcomes of early-stage CSCC patients. AGK can be used as an independent prognostic marker for early-stage CSCC.